GlassScriptPhysician profile
Paul Gibbons
NPI 1073591426
$21,281.82
in general payments reported to CMS, 2019-2025
61 companies · $3,095 in 2025
The $3,095 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,632 · 2020: $2,315 · 2021: $3,108 · 2022: $3,624 · 2023: $3,545 · 2024: $2,963 · 2025: $3,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,584 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,583.56 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,682.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,383.36 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $2,239.66 | 2019-2025 | |
| Novo Nordisk INC | $2,009.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,744.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,395.79 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $870.73 | 2019-2023 | Repatha, Otezla, Prolia |
| Astellas Pharma US INC | $788.10 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $574.87 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $551.80 | 2019-2024 | Jardiance, Ofev |
| Biohaven Pharmaceutical Holding Company LTD. | $515.49 | 2022 | |
| Amarin Pharma, INC. | $451.74 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $402.27 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $359.42 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $345.13 | 2019-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gibbons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.